We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Department of Pharmacology, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co- Ed.), Tarnaka, Hyderabad, Telangana, India-500017.
Drug-induced liver injury (DILI) remains a major obstacle in drug development and clinical therapy, often causing severe hepatic damage and treatment withdrawal. Experimental animal models are indispensable for elucidating DILI mechanisms, discovering biomarkers, and testing hepatoprotective agents before human trials. This overview synthesizes evidence from peer-reviewed studies on commonly used models-rats, mice, rabbits, guinea pigs, and zebrafish-exposed to hepatotoxins such as paracetamol, carbon tetrachloride, thioacetamide, methotrexate, diclofenac, isoniazid, sodium valproate, gentamicin, and carbamazepine. Dosing regimens, administration routes, exposure durations, and resulting biochemical and histopathological alterations were critically evaluated. Rats and mice predominate due to their reproducibility and physiological similarity to human liver function. Rabbits, guinea pigs, and zebrafish provide complementary advantages for specific toxicological questions, including immune-mediated injury and high-throughput screening. Collectively, these models enable robust investigation of DILI pathogenesis, biomarker validation, and preclinical assessment of safer therapeutics and hepatoprotective strategies.
The liver is a primary organ involved in the metabolism, detoxification, protein synthesis, bile production.[1] The human liver has remarkable regenerative capacity; however, repeated or persistent injury overwhelms its repair mechanisms.[2] The clinical manifestations range from asymptomatic elevations in liver enzymes to acute hepatitis, cholestasis, chronic liver disease, and acute liver failure.[3]
Damaged hepatocytes release danger-associated molecular patterns (DAMPs), activating Kupffer cells and recruiting inflammatory cells that amplify hepatic injury.[4] It remains one of the principal reasons for discontinuing clinical trials and withdrawing approved drugs from the market.[5]
Clinical evaluation is commonly supported by biochemical markers such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), bilirubin, and histopathological examination.[6]
Liver injury is a significant global health issue, leading to both acute and chronic problems. [7] In the past two decades, liver injury causes have changed notably. Viral hepatitis remains a major issue in low- and middle-income countries, while in Western countries, drug-induced liver injury (DILI) is a leading cause of acute liver failure and a common reason for drug withdrawals. Over 1,000 medications, herbs, and supplements have been linked to liver damage. The estimated yearly incidence is 14 to 19 cases per 100,000 people, though the real number is probably higher due to under-reporting. [8]
Most studies show that DILI is more common in older adults due to multiple medications, health conditions, and age-related changes in how drugs are processed. While women might be more prone to severe liver damage from some drugs, overall, there is no clear difference in DILI rates between men and women.[9]
Each year, there are about 310 million new cases worldwide, with nearly 2 million deaths and 63.5 million DALYs. While overall global rates have fallen, deaths and DALYs have risen in High-income North America and Australasia, mainly due to increasing cases of fatty liver disease and alcohol-related liver conditions.[7]
The below figure 1 depicts DILI cases from 2012 to 2025, demonstrating an overall increasing trend in the number of reported cases, with a notable rise after 2017. The rise reflects both an actual increase in certain causes of DILI and a substantial improvement in case detection and reporting, rather than a sudden biological increase in liver injury. Rising use of herbal and dietary supplements, new liver-toxic drugs like cancer immunotherapies, greater physician awareness, expanded DILI registries, improved diagnosis and reporting.

Figure 1: Annual Reported DILI Cases (2012–2025)
In India, data from the Indian Network for Drug-Induced Liver involving 1,288 patients showed that approximately 10% developed acute liver failure, highlighting the substantial disease burden. Morbidity is particularly high among patients receiving anti-tuberculosis drugs, herbal medicines, anticonvulsants, and certain antibiotics.[10]
People affected often face liver dysfunction, extended hospital stays, a lower quality of life, frequent readmissions, and may develop cirrhosis or liver cancer over time. Advanced stages of liver disease can lead to serious issues like portal hypertension, fluid buildup (ascites), brain dysfunction (hepatic encephalopathy), kidney problems, and infections, all of which contribute to heavy healthcare demands and disability.[8]
Early diagnosis, prompt withdrawal of the offending drug, and timely referral for liver transplantation are critical measures to reduce morbidity and mortality.[53] In the Indian INDILI registry, the overall mortality was 12.3%, whereas mortality increased dramatically to 64.8% among patients with DILI-associated acute liver failure (DILI-ALF). Prospective population-based studies have reported lower mortality in the general population because many cases are mild. For example, mortality rates were 5.9% in France, 1% in Iceland, and 0.39% in China, illustrating considerable geographic variation depending on patient characteristics, causative agents, and healthcare systems.[4] The risk of death differs depending on the drug responsible, the extent of liver damage, the patient’s age, and whether any pre-existing liver disease is present. [4]
The etiology of DILI is multifactorial and involves interactions between drug characteristics and host susceptibility. Major pathogenic mechanisms include reactive metabolite formation, oxidative stress, mitochondrial dysfunction, immune-mediated hepatotoxicity, disruption of bile acid homeostasis, and genetic predisposition. Recent studies emphasize that idiosyncratic DILI results from a combination of genetic susceptibility, adaptive immune activation, and environmental factors rather than a single pathogenic pathway as shown in figure 2.

Figure 2: Multifactorial Risk Factors Contributing to Drug Induced Liver Injury
Types of DILI:
DILI is categorized based on three factors: Mechanism of injury, the pattern of liver enzyme changes, and the clinical or tissue characteristics observed,shown in the table 1.
Table 1: Classification of DILI Based on Mechanism of Injury, Biochemical Pattern, and Clinical Phenotype
| Classification Type | Description | Key Features | Ref |
|---|---|---|---|
| Mechanism of Injury | |||
| Intrinsic (Direct) DILI | Liver damage caused directly by the drug or its toxic metabolites, usually dose-related | Dose-dependent, predictable, rapid onset (hours to days), reproducible in animals, linked to overdoses | 11,12 |
| Idiosyncratic DILI | Unpredictable liver injury involving immune responses, often linked to genetic factors | Dose-independent, unpredictable timing, variable onset, not reproducible in animals, immune/metabolic involvement | 12,13, 14,15 |
| Indirect DILI | Liver damage caused indirectly through effects on the immune system or liver function | Occurs later, related to drug effects (e.g., cancer immunotherapies), not direct liver toxicity | 16 |
| Biochemical Pattern | |||
| Hepatocellular DILI | Damage mainly to liver cells, identified by high ALT levels and R-value ≥ 5 | ALT ≥ 3x ULN, R-value ≥ 5, highest risk for acute liver failure | 12,16, |
| Cholestatic DILI | Injury affecting bile production or flow, with high ALP levels and R-value ≤ 2 | ALP ≥ 2x ULN, R-value ≤ 2, symptoms include jaundice and itching | 12,16 |
| Mixed DILI | Combination of liver cell and bile flow injury, with intermediate R-value | ALT ≥ 3x ULN, ALP ≥ 2x ULN, R-value between 2 and 5 | 12,16 |
| Clinical Phenotype | |||
| Various phenotypes | Different liver conditions identified by symptoms and liver tissue analysis | Includes acute hepatitis, cholestatic hepatitis, autoimmune hepatitis, steatosis, chronic hepatitis, sinusoidal obstruction syndrome | 12,16 |
*ALT = Alanine aminotransferase
*ALP = Alkaline phosphatase
*ULN=Upper limit of normal
Severity Grades of DILI:
The DILIN grading system is the most commonly adopted method for classifying the severity of liver injury:[17]
Drugs That Cause Liver Injury in Humans: According to the FDA DILI (Drug injured liver injury) rank database and published human hepatotoxicity studies, drugs consistently associated with liver injury include. [18,19,20,21,22,23,24,25,26]
Table 2: Common Drug and Supplement Categories Linked to Liver Injury and Their Characteristics
| Drug Class | Key Drugs | Liver Injury Pattern |
|---|---|---|
| NSAIDs | Acetaminophen, Diclofenac, Ibuprofen | Acetaminophen: dose-dependent: others: idiosyncratic |
| Antibiotics | Amoxicillin–clavulanate, Isoniazid, Rifampicin | Common cause of idiosyncratic DILI worldwide |
| Antiepileptics | Valproic acid, Carbamazepine, Phenytoin | Mitochondrial dysfunction or immune-mediated |
| Antitubercular | Isoniazid, Rifampicin, Pyrazinamide | Frequent hepatotoxicity in combination therapy |
| Antifungals | Ketoconazole, Itraconazole, Fluconazole | Cholestatic or mixed; ketoconazole: high risk |
| Cardiovascular | Amiodarone, Statins, Methyldopa | Amiodarone: steatosis; statins: mild enzyme rise |
| Anticancer | Methotrexate, Cisplatin, Imatinib | Transient enzymes to fibrosis/hepatic failure |
| Antiretrovirals | Nevirapine, Efavirenz, Ritonavir | Hypersensitivity, mitochondrial, or immune-mediated |
| Immunosuppressants | Azathioprine, Tacrolimus, Cyclosporine | Cholestatic or vascular liver injury |
Animal Models For DILI:
Based on the hepatotoxic agent employed, these models are often divided into drug-induced and chemical-induced liver injury models.
Drugs that can induce liver injury:
Many drugs can cause damage to the liver. Some, like acetaminophen, directly harm the liver, while others, such as amoxicillin-clavulanate, isoniazid, and statins, tend to cause unpredictable, immune-related liver injury. Often arise when these drugs are converted into reactive substances or trigger immune responses. [12]
Chemicals frequently reported in experimental hepatotoxicity studies:
This figure highlights the key ways drugs can cause liver damage, showing the liver at the center to illustrate how various cellular and molecular processes can each, or together, lead to harm. These processes include oxidative stress, the creation of reactive metabolites that bind to liver cells, stress in the endoplasmic reticulum, mitochondrial problems, immune-related damage, DNA harm with faulty repair, disturbances in bile acid balance (cholestasis), and cell death through apoptosis or necrosis. It also points out common drugs like acetaminophen, diclofenac, isoniazid, methotrexate, carbamazepine, valproate, thioacetamide, carbon tetrachloride, and gentamicin, which can trigger liver injury via one or more of these pathways. Overall, the figure shows that drug-induced liver injury is a complex process where overlapping factors combine to cause liver cell dysfunction, inflammation, and damage.

Figure_3 Major Mechanisms of DILI and Representative Hepatotoxic Drugs

Figure_4 Estimated Percentage Distribution of Drug Classes Causing Drug-Induced Liver Injury.
Paracetamol (Acetaminophen): At normal therapeutic doses, paracetamol is safely metabolized mainly through glucuronidation and sulfation. During an overdose, however, it is converted by CYP2E1, CYP1A2, and CYP3A4 enzymes into the toxic metabolite NAPQI. When glutathione stores become depleted, NAPQI accumulates, triggering oxidative stress, mitochondrial damage, ATP depletion, and ultimately causing centrilobular liver cell injury and death.[27]
This model is quick and reliable, effectively replicating the acute liver damage seen in human overdoses. However, it only reflects acute injury and differs based on species and dosage.
Paracetamol is widely used in animal studies, especially with mice and rats, to mimic human liver injury. Mice receive 200-500 mg/kg and rats 500-1000 mg/kg, orally or by injection, with liver damage appearing within 24 hours. This damage includes liver cell death, oxidative stress, and mitochondrial problems, helping researchers study liver injury and test treatments. [28,27]
Diclofenac: Diclofenac is metabolized into reactive quinone-imine compounds that bind to liver proteins, impair mitochondrial respiration, increase the formation of reactive oxygen species, along with promote programmed cell death and liver cell necrosis.[28]
Diclofenac is used in rats and mice to study both unpredictable and direct liver injury, particularly involving the immune system. The limitation is its low consistency and the need for long-term dosing. Animals are given 10 to 50 mg/kg orally or by injection for 7 to 14 days. This treatment causes a combination of liver cell damage, bile flow problems, and inflammation, helping researchers explore different types of liver injury. [29]
Isoniazid (INH): Isoniazid is broken down into hydrazine and acetyl hydrazine, which cause oxidative stress, disrupt mitochondrial function, reduce glutathione levels, and result in the death of hepatocytes. [30]
This model is relevant clinically for tuberculosis drug toxicity and helps investigate mitochondrial damage. The challenges include variable animal sensitivity and a slow progression of liver injury.
Isoniazid is frequently used rats, mice, and guinea pigs to investigate the unpredictable liver damage associated with tuberculosis therapy. The drug is given orally at a dose of 50–100 mg/kg body weight per day for 14–28 consecutive days.[31]
Methotrexate (MTX): Chronic exposure to methotrexate causes oxidative stress, damages mitochondria, stimulates inflammatory cytokine release, activates hepatic stellate cells, promotes collagen accumulation, and results in liver fibrosis.[32]
Ideal for researching chronic liver fibrosis and oxidative stress, though it requires extended treatment periods and shows less acute liver damage.
Methotrexate is used in animal studies with rats, mice, and rabbits to mimic chronic liver toxicity seen in cancer and autoimmune treatments. Rats typically receive 0.3 to 1 mg/kg by injection once a week for 4 to 8 weeks. This causes liver cell damage, scarring, and oxidative stress, helping researchers understand long-term drug-induced liver injury. [31]
Thioacetamide: Thioacetamide is converted into reactive intermediates thioacetamide-S-oxide and thioacetamide-S,S-dioxide, which generate reactive oxygen species, cause lipid peroxidation, DNA damage, liver cell death, and eventually lead to liver fibrosis. [33] However, it isn’t a therapeutic drug and can cause severe toxicity and high death rates at high doses.
Thioacetamide is frequently used in research involving rats and mice to create models of liver fibrosis and cirrhosis, which mimic chronic liver damage. However, it isn’t a therapeutic drug and can cause severe toxicity and high death rates at high doses.
It is typically given either by injection into the abdomen or orally, usually at doses between 100 and 300 mg per kilogram of body weight, administered two to three times a week for up to eight weeks.[34]
Carbon Tetrachloride (CCl₄): CCl₄ is metabolized by the enzyme CYP2E1 into trichloromethyl radicals, which trigger lipid peroxidation, oxidative stress, damage to cell membranes, and death of liver cells. This process has been well-established in experimental models of CCl₄-induced liver injury.[35]
A well-established, straightforward model for studying fibrosis and cirrhosis with good reproducibility. It’s a chemical toxin rather than a medication, limiting its clinical relevance to drug-induced liver injury.
Carbon tetrachloride is commonly used in animal studies with rats, mice, rabbits, and guinea pigs. Widely used to cchronic liver injury and fibrosis. It causes liver cell damage and oxidative stress. Animals usually receive doses of 0.5 to 1.0 mL/kg by injection or orally, given 2-3 times a week for several weeks. This leads to liver tissue death, inflammation, and scarring, helping researchers study long-term liver damage. [37]
Sodium valproate: It is chemically known as 2-propylpentanoic acid, is a versatile antiepileptic drug commonly used to manage epilepsy, bipolar disorder, and prevent migraines. As a branched-chain fatty acid, VPA undergoes significant metabolism in the liver, which is closely associated with its liver toxicity. Silva et al. identified mitochondrial β-oxidation as the main metabolic route for VPA, with disruption of this process being a key factor in its toxic effects.
This model mimics mitochondrial issues and fatty liver disease (steatosis), but often results in mild liver injury and variable reproducibility across species.
Sodium Valproate is widely used in rat and mouse models to mimic mitochondrial toxicity and liver fat accumulation caused by valproate treatment. Typically administer doses between 200 and 600 mg/kg, either orally or through injection, for a period of 7 to 14 days.[31]
In mice,the treatment consists of administering the compound orally at a dose of 400 mg/kg/day for 21 consecutive days.
Gentamicin: Gentamicin is a broad-spectrum aminoglycoside antibiotic produced by Micromonospora purpurea. It is commonly used to manage severe infections caused by aerobic Gram-negative bacteria and may be administered with β-lactam antibiotics to enhance bactericidal activity against certain Gram-positive organisms.[38]
Useful for exploring oxidative stress and combined liver-kidney toxicity, although it mainly affects the kidneys, with only mild liver injury.
Gentamicin is studied primarily in rats, mice, and rabbits for its toxic effects on the kidneys, but it also causes liver damage. It is widely used to explore liver injury related to oxidative stress. The typical experimental dose ranges from 40 to 100 mg/kg, given intraperitoneally once daily for 7 to 14 days. [31]
Crabamazepine: Carbamazepine is a first-generation anticonvulsant used to treat epilepsy, trigeminal neuralgia, and bipolar disorder. It stabilizes overactive neurons by blocking voltage-gated sodium channels, reducing abnormal brain activity. After oral intake, it’s well absorbed and metabolized in the liver to an active form. Its unique feature is autoinduction, where prolonged use speeds up its own metabolism, shortening its elimination half-life.[39]
It models unpredictable and immune-related liver damage and is clinically relevant. However, liver injury is rare in animals, making this model less consistent.
Carbamazepine is tested on rats and mice to investigate unpredictable liver damage that is often immune-related. The drug is administered at doses of 50 to 100 mg/kg, orally or by injection, for 14 to 28 days.[31]
Table 3: Changes in Biomarkers Commonly Reported in Experimental DILI
| Hepatotoxicity | Animal model | Dose | Route | Duration |
|---|---|---|---|---|
| Paracetamol (Acetaminophen) | Rats (Wistar) | 1000–2000 mg/kg, | Oral Or Intraperitoneal |
Single dose or 1–2 days |
| Mice (C57BL/6 or BALB/c) | 300–500 mg/kg | Intraperitoneal | 6 weeks | |
| Rabbit | 2 g/kg | Intragastric, Oral | 1-3 days | |
| Zebrafish (Wild type embryos) | 500–5000 μM | Immersion | 72–120 hpf (hours post fertilization) | |
| Diclofenac | Rats (Wistar) | 10–100 mg/kg/day | Oral, Intraperitoneal |
7–28 days |
| Mice (BALB/c) | 30–150 mg/kg | Intraperitoneal ,oral |
3 days | |
| Isoniazid | Rats (Wistar) | 50–100 mg/kg/day | Oral | 14–28 days |
| Mice (C57BL/6) | 50–200 mg/kg | Oral | Acute | |
| Zebrafish | 1–10 mM | Immersion | 72–96 h | |
| Methotrexate | Rats (Wistar) | 10-20mg/kg /week | Intraperitoneal | 4–8 weeks |
| Mice (C57BL/6) | 20 mg/kg | Intraperitoneal | 1 week | |
| Rabbit | 20 mg/kg | Intraperitoneal | Days 1 & 7 | |
| Zebrafish | 1.5 mM | Immersion | 6–72 hpf | |
| Thioacetamide (TAA) | Rats (Wistar) | 100–300 mg/kg | Intraperitoneal 2–3 times/week |
6–12 weeks |
| C57BL/6 | 200 mg/kg | Intraperitoneal | Single dose | |
| Guinea pig (Hartley) | 25–100 mg/kg | Intraperitoneal | Single dose | |
| Carbon Tetrachloride (CCl₄) | Rats (Wistar) | 0.5–2 mL/kg (1:1 in olive oil) | Intraperitoneal | twice weekly for 4–8 weeks |
| Mouse (C57BL/6) | 1mL/kg (1:3 in corn oil) | Intraperitoneal | Single dose | |
| Rabbit | 0.5–1 mL/kg | Oral | Single dose | |
| Sodium valproate | Rats (Wistar) | 300–500 mg/kg/day | Oral | 14–28 days |
| Guinea pig (Hartley) | 20–600 mg/kg | Intravenous | Acute | |
| Gentamicin | Rats (Wistar) | 80 mg/kg/day | Intraperitoneal | 7–8 days |
| Mice (Swiss albino) | 100 mg/kg/day | Intraperitoneal | 10 days | |
| Carbamazepine | Rats (Wistar) | 50–100 mg/kg/day | Oral | 14–28 days |
| Mice (BALB/c) | 50 mg/kg/day | Oral | 5 days |
Biomarkers Of Liver Injury:
Liver injury is commonly assessed by measuring specific biochemical markers in the blood that reflect hepatocellular damage and impaired liver function. Among these:
Physical Parameters
Body Weight: Body weight and liver weight are routinely measured in experimental DILI studies because they reflect the overall health of the animals and the severity of hepatic injury. Drug-induced hepatotoxicity is commonly associated with reduced body weight gain due to decreased food intake, metabolic disturbances, and systemic toxicity.] Most hepatotoxic drugs reduce body weight due to systemic toxicity.[40]
Liver-Specific Biochemical Parameters
Oxidative Stress Markers
Inflammatory Markers:
Major Biomarkers And Their Responses In Experimental DILI Models:
The table 4 represents the biochemical and physiological alterations observed during drug-induced liver injury (DILI) in animal models. The changes in these biomarkers indicate the extent of liver damage, oxidative stress, and inflammatory responses.
Table 4: Changes in Biomarkers Commonly Reported in Experimental DILI
| Biomarker | Change in DILI | Range in DILI animal studies |
|---|---|---|
| Body weight | ↓ Decrease | 5-20% reduction from baseline |
| Liver weight | ↑ Increase | 10-40% increase (relative liver weight) |
| AST (U/L) | ↑ Increase | 150–1500 U/L |
| ALT (U/L) | ↑ Increase | 200–3000 U/L |
| ALP (U/L) | ↑ Increase | 120–450 U/L |
| Total Bilirubin (mg/dL) | ↑ Increase | 0.8–4.5 mg/dL |
| Albumin (g/dL) | ↓ Decrease | 2.0–3.5 g/dL |
| LDH (U/L) | ↑ Increase | 400–3000 U/L |
| MDA (nmol/mg protein) | ↑ Increase | 2–8 nmol/mg protein |
| GSH (μmol/g tissue) | ↓ Decrease | 20–70% depletion |
| SOD (U/mg protein) | ↓ Decrease | 20–60% reduction |
| Catalase (U/mg protein) | ↓ Decrease | 20–60% reduction |
| TNF-α | ↑ Increase | 2–8 fold increase |
| IL-1β | ↑ Increase | 2–6 fold increase |
| IL-6 | ↑ Increase | 2–10 fold increase |
| NF-κB expression | ↑ Increase | 1.5–5 fold increase |
Histopathological Features of Liver Injury:
Liver injury is marked by a range of microscopic changes that reveal the extent and nature of cellular damage along with the body’s inflammatory response. A key feature often observed is:
Future Perspectives in Liver Injury Research
REFERENCES
Kukkali Sneha, Udutha Bharathi, Dr. Venu Talla, Preclinical Models for Drug-Induced Liver Injury with Special Focus on Biomarkers Involved in Pathomechanism, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 11, 2638-2651. https://doi.org/10.5281/zenodo.24301318
10.5281/zenodo.24301318